Cory berkland. Cory Berkland; Published in issue: February 2015. p346-361. Full-Text...

Wei Bin Fang 1, Min Yao , Gage Brummer , Diana Acevedo , Nabil Alhaka

Cory J. Berkland [email protected] Department of Chemical and Petroleum Engineering, University of Kansas, 1530 West 15th Street, Lawrence, KS, 66045 USA. Department of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Avenue, Lawrence, KS, 66047 USA. E-mail: [email protected] Search for more papers by this authorCory Berkland: Resources, Writing - review & editing. Michael J. Hageman: Writing - review & editing, Project administration, Supervision, Resources. Declaration of Competing Interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work …Cory Berkland Laird Forrest Michael Hageman Jeff Krise Sue Lunte Russ Middaugh Christian Schöneich Teruna Siahaan John Stobaugh Thomas Tolbert David Volkin Michael Wang Undergraduate Research Program ...Our clinical studies will determine if BBI-001 can reduce or eliminate the need for lifelong phlebotomies in Hereditary Hemochromatosis patients,” said Dr. Cory Berkland, Bond’s CEO, Chairman ...Cory Berkland Professor Biomedical Engineering [email protected] Google Scholar Education PhD, University of Illinois, 2003 MS, University of Illinois, 2001 BS, Iowa State University, 1998 Research areas Advanced Materials Biomedical, Bio-inspired, and Bio-derived Materials Cell & Molecular Bioengineering Regenerative Engineering in MedicineCory Berkland The University of Kansas Verified email at ku.edu. ... L Wang, CJ Berkland, MS Detamore. Annals of biomedical engineering 38, 2167-2182, 2010. 136: 2010: Pulmonary delivery of vancomycin dry powder aerosol to intubated rabbits Bradley P. Sullivan1,#, Nashwa El-Gendy1,3,#, Christopher Kuehl1, and Cory Berkland1,2,* 1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas, 66047 2Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, Kansas, 66045 3Department of Pharmaceutics and Industrial ...Cory Berkland was associated with Savara Pharmaceuticals in 2019. They may have been associated with this organization before or after this year as well. Savara Pharmaceuticals Business Data 900 S Capital Of Texas Hwy, Ste 150, Austin, Texas, 78746-5436 (512) 961-1891PARKVILLE, Mo.--(BUSINESS WIRE)-- Bond Biosciences, Inc."We are pleased to begin this first-in-human clinical trial of our lead non-absorbed oral therapy and thankful for the seasoned development team that contributed to this significant milestone," said Dr. Cory Berkland, Bond's CEO, Chairman of the Board and Co-founder.Dr. Cory Berkland Solon E. Summerfield Distinguished Professor School of Engineering, School of Pharmacy Chemical and Petroleum Engineering, Pharmaceutical Chemistry RESEARCH INTERESTS Antigen-specific immunotherapies, sequestering cells to combat autoimmunity, autoimmunity and tolerance reintroduction, targeted drug delivery, and gene delivery.Cory Berkland The University of Kansas Verified email at ku.edu. ... L Wang, CJ Berkland, MS Detamore. Annals of biomedical engineering 38, 2167-2182, 2010. 136: 2010: INTRODUCTION. Autoimmune diseases, such as multiple sclerosis (MS), 1, 2 type 1 diabetes (T1D), 3-7 neuromyelitis optica, 8, 9 and lupus erythematosus, 10, 11 involve loss of tolerance to self-antigens in autoreactive B cells, leading to tissue damage, disability, and death. In individuals afflicted by T1D, the insulin-producing beta cells in the pancreas are targeted by an autoimmune ...Cory Berkland Songyot Anuchapreeda: Keywords: Agricultural and Biological Sciences;Biochemistry, Genetics and Molecular Biology;Chemistry: Issue Date: 1-Jan-2021: Abstract: The magnolia plant has been used in traditional medicine since ancient times. This study was designed to investigate the effects of active compounds from Thai Champi ...Cory Berkland is a professor of pharmaceutical chemistry and chemical and petroleum engineering at the University of Kansas. (Berkland Tr. 593) The Court recognized Dr. Berkland as an expert in the preparation and analysis of pharmaceutical formulations.Nanotechnology in vaccine delivery. Adv Drug Deliv Rev2008 May 22;60 (8):915-28. doi: 10.1016/j.addr.2007.05.017. Epub 2008 Feb 7. Laura J Peek , C Russell Middaugh , Cory Berkland. Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047 USA. PMID: 18325628. PMCID: PMC7103321. 10.1016/j.addr.2007.05.017. With very few ...16‏/05‏/2014 ... The principal investigator from the University of Kansas for the project is Cory Berkland, KU professor of chemical and petroleum engineering ...BERKLAND CORY, WANG QUN. Author information. Affiliations. All authors. 1. UNIV KANSAS Patent: Publ. of Application with search report - European Patent Office Application: EP20080848334 on 06 Nov 2008 Publication: 06 Nov 2008 PAT: EP2217295 . Patent. Share this article ...Jun 12, 2017 · Brittany L Hartwell 1 , Chad J Pickens 2 , Martin Leon 3 , Cory Berkland 1 2 4 Affiliations 1 Bioengineering Graduate Program, University of Kansas 1520 West 15th Street, Lawrence, Kansas 66045, United States. Jun Yang, Sheng-Xue Xie, Yiling Huang, Min Ling, Jihong Liu, Yali Ran, Yanlin Wang, J Brantley Thrasher, Cory Berkland, Benyi Li. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine 2012, 7 (9) , 1297-1309.Amir Fakhari 1 , Quang Phan, Santosh V Thakkar, C Russell Middaugh, Cory Berkland. Affiliation 1 Bioengineering Graduate Program, University of Kansas, Lawrence, Kansas 66045, USA. PMID: 23514620 DOI: 10.1021/la304575x Abstract Hyaluronic acid (HA) is a glycosaminoglycan with diverse biomedical applications including viscosupplementation of ...Mar 30, 2021 · Our clinical studies will determine if BBI-001 can reduce or eliminate the need for lifelong phlebotomies in Hereditary Hemochromatosis patients,” said Dr. Cory Berkland, Bond’s CEO, Chairman ... Deanna Diaz, "Utilizing Fluorescent Soluble Antigen Arrays for B Cell Detection," mentored by Cory Berkland, Solon E. Summerfield Distinguished Professor of Pharmacy Connor Dougan , "PERIOD, Period: Student Analysis of the Effectiveness of The University of Kansas' and PERIOD's Free Menstrual Products on Campus," mentored by Ivery ...Co-Founder & Chief Executive Officer at Context Therapeutics. Mr. Lehr is the Co-founder and CEO of Context Therapeutics. In addition, Mr. Lehr is a member of the Scientific Advisory Board of Integral Molecula r, an antibody discovery company. Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research ...Cory Berkland The University of Kansas Verified email at ku.edu. Limin Wang rice university Verified email at rice.edu. ... MM Bailey, SR Kline, MD Anderson, JL Staymates, C Berkland. Journal of applied polymer science 126 (4), 1218-1227, 2012. 10: 2012: Fluorinated polymers and associated methods. C Berkland, M Bailey. US Patent App. 12/ ...Alhakamy, Nabil A; Nigatu, Adane S; Berkland, Cory J et al. (2013) Noncovalently associated cell-penetrating peptides for gene delivery applications. Ther Deliv 4:741-57 Alhakamy, Nabil A; Berkland, Cory J (2013) Polyarginine molecular weight determines transfection efficiency of calcium condensed complexes. Mol Pharm 10:1940-8Abstract. Lung surfactant is crucial for optimal pulmonary function throughout life. An absence or deficiency of surfactant can affect the surfactant pool leading to respiratory distress. Even if the coupling between surfactant dysfunction and the underlying disease is not always well understood, using exogenous surfactants as replacement is ... Loop is the open research network that increases the discoverability and impact of researchers and their work. Loop enables you to stay up-to-date with the latest discoveries and news, connect with researchers and form new collaborations.Supang Khondee, Tatyana Yakovleva, Cory Berkland. First published: 04 August 2010. https://doi.org/10.1002/app.32460. Citations: 2. Read the full text. PDF. …Singkome Tima, Songyot Anuchapreeda, Chadarat Ampasavate, Cory Berkland, Siriporn Okonogi. Stable curcumin-loaded polymeric micellar formulation for enhancing cellular uptake and cytotoxicity to FLT3 overexpressing EoL-1 leukemic cells. European Journal of Pharmaceutics and Biopharmaceutics 2017, 114, 57-68. DOI: …Cory Berkland, distinguished professor of chemical and petroleum engineering. Lisa Friis, professor of mechanical engineering. Anil Misra, professor of civil, environmental and architectural engineering. Steven Soper, foundation distinguished professor of mechanical enginering and chemistry. Paulette Spencer, distinghuished professor of ...Cory Berkland, PhD. WIZARD FEATURES. © 2023 DeKosky Lab.Bond Biosciences has a strong board and managment team with significant industry experience including Cory Berkland, Mike Riley, Tim Opler and Mike Beckloff. 1. Introduction. Fixed dose combinations (FDCs) are defined as a combination of two or more active ingredients within a single form of pharmaceutical administration [Citation 1 – Citation 6].They have been shown to appreciably reduce the risk of medication non-adherence, which is particularly important in patients with chronic diseases [Citation …Cory Berkland Solon E. Summerfield Distinguished Professor Department of Pharmaceutical Chemistry Contact Info [email protected] 785-864-1455 Multidisciplinary Research Building, Room 320E 2030 Becker Drive Lawrence, KS 66047 Personal Links Cory Berkland Research Education — Ph.D. in Chemical and Biomolecular Engineering, University of IlliniosCory Berkland. Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, Kansas 66045. Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66045. Search for more papers by this author. Stephen Johnson, Corresponding Author.Dr. Cory Berkland is Chairman of the Board, President, CEO, and Co-Founder of Bond Biosciences. He is Distinguished Professor at The University of Kansas and has extensive experience founding, growing, and exiting pharmaceutical companies including Orbis Biosciences and Savara Pharmaceuticals. What We Do. Our lab works at the interface of medicine and engineering with an emphasis on precisely controlling the physical and chemical properties of particles and biomaterials. The lab environment fosters multidisciplinary interaction between graduate and undergraduate researchers from the departments of Chemical and Petroleum …Hyaluronic acid (HA) is a naturally occurring biodegradable polymer with a variety of applications in medicine, including scaffolding for tissue engineering, dermatological fillers and viscosupplementation for osteoarthritis treatment. HA is available in most connective tissues in body fluids such as synovial fluid and the vitreous humor of …The long-term objective of this application is to deliver a unique biomaterial that can easily be molded into place by a surgeon, and will resorb as it induces rapid tissue regeneration. Toward this o...Cory Berkland, PhD. WIZARD FEATURES. © 2023 DeKosky Lab.The AIRR Community Guide to Quality Control: Chain Pairing Precision and Monitoring of Cross-Sample Contamination. Chung C-Y, Gutiérrez-González M, López Acevedo SN, Fahad AS, DeKosky BJ. Immunogenetics: Methods and Protocols, Methods in Molecular Biology, y, (Springer Nature) ISBN: 9781071621141 , 2022. Antibodies Computational immunology ...Cory Berkland has 3 current jobs including Co-founder and Chief Executive Officer at Bond Biosciences, Co-founder and Chief Scientific Officer at Bond Biosciences, and Solon E. Summerfield Distinguished Professor at University of Kansas. Additionally, Cory Berkland has had 1 past job as the Chief Science/Scientist at Orbis Biosciences.Cory Berkland Co-founder and Chief Executive Officer at Bond Biosciences Solon E. Summerfield Distinguished Professor at The University of Kansas 3yMar 1, 2011 · 1. Introduction. Injectable scaffolds have received attention due to their potential for avoiding the invasive surgery typically required for tissue implantation. 1 From a clinical perspective, the use of injectable materials is an attractive alternative to surgery as it reduces the risk of infection, scar formation, patient discomfort and the cost of treatment. 2 Injectable scaffolds may be ... Cory Berkland. The University of Kansas. ... CJ Berkland, ML Forrest. Advanced drug delivery reviews 61 (6), 457-466, 2009. 897: 2009: Nanotechnology in vaccine delivery. Hartwell BL; Pickens CJ; Leon M; Berkland C, Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis. Biomacromolecules 2017, 18 (6), 1893–1907. [PMC free article] [Google Scholar]The toll-like receptor 7 and 8 (TLR7/8) agonist Resiquimod (R848) has been recognized as a promising immunostimulator for the treatment of cutaneous cancers in multiple clinical trials. However, systemic administration of R848 often results in strong immune-related toxicities while having limited th …Sep 24, 2021 · 1. Introduction. Leukemia is among the top 10 cancers diagnosed globally. It is a group of cancers of early blood-forming cells, which are characterized by the uncontrolled production and accumulation of blast or immature abnormal blood cells in the peripheral blood and bone marrow. Nov 11, 2020 · Chad Groer, 1 Ti Zhang, 1 Ruolin Lu, 2 Shuang Cai, 1 Derek Mull, 1 Aric Huang, 2 Melanie Forrest, 1 Cory Berkland, 2, 3 Daniel Aires, 1, 4 and Marcus Laird Forrest 1, 2, * Chad Groer 1 HylaPharm LLC, Lawrence, Kansas Jun 12, 2017 · Brittany L Hartwell 1 , Chad J Pickens 2 , Martin Leon 3 , Cory Berkland 1 2 4 Affiliations 1 Bioengineering Graduate Program, University of Kansas 1520 West 15th Street, Lawrence, Kansas 66045, United States. About. My PhD work in Bioengineering at the University of Kansas was performed under the advisement of Dr. Cory Berkland. My research entails the fabrication and validation of a high throughput ...LAWRENCE — Cory Berkland might not be the first person you’d guess would help to create what has become a multimillion-dollar company. The distinguished professor, appointed in the departments of Pharmaceutical Chemistry and Chemical & Petroleum Engineering at the University of Kansas, grew up on a pig farm in Iowa, studied chemical engineering at the undergraduate and graduate levels and ...Cory Berkland. E-mail: [email protected]; Vladimir Birman Associate Professor of Chemistry McMillen 409. E-mail: [email protected]; Phone: 314-935-9188 John Bleeke Jian Qian, Bradley P. Sullivan, Samuel J. Peterson, and Cory Berkland . Nonabsorbable Iron Binding Polymers Prevent Dietary Iron Absorption for the Treatment of Iron Overload. ACS Macro Letters 2017, 6 (4) , 350-353. DOI: 10.1021/acsmacrolett.6b00945. Anindita Das and Patrick Theato .Cory Berkland Professor Biomedical Engineering [email protected] Google Scholar Education PhD, University of Illinois, 2003 MS, University of Illinois, 2001 BS, Iowa State University, 1998 Research areas Advanced Materials Biomedical, Bio-inspired, and Bio-derived Materials Cell & Molecular Bioengineering Regenerative Engineering in Medicine Patent number: 10398649. Abstract: Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles. Type: Grant. Filed: October 16, 2017. Date of Patent: September 3, 2019. Assignee: Orbis Biosciences, Inc. Inventors: Cory Berkland, Milind Singh.Home. People. Cory Berkland, Ph.D. -Solon E. Summerfield Distinguished Professor. -Chemical and Petroleum Engineering. -Pharmaceutical Chemistry. Contact Info. …Nov 22, 2019 · Jian Qian 1 , Cory Berkland 2 Affiliations 1 Department of ... Electronic address: [email protected]. PMID: 31655253 PMCID: PMC6820273 DOI ... Conflict of interest C. Berkland has a patent (US 20110287547 A1) on Ca-TAT peptides. These studies were not solicited or funded by any pharmaceutical company. ... Cory Berkland, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.Singkome Tima; Siriporn Okonogi; Chadarat Ampasavate; Cory Berkland; Songyot Anuchapreeda: 1-Jan-2009: HPLC determination of mangostin and its application to storage stability study: Pathom Jujun; Krisana Pootakham; Yanee Pongpaibul; Prasit Tharavichitkul; Chadarat Ampasavate: 16-Feb-2016Cory Berkland, PhD. WIZARD FEATURES. © 2023 DeKosky Lab.That effort led to an NIH grant with Cory Berkland, Ph.D., of the University of Kansas, as principal investigator. Flash forward to present day and Detamore is a principal investigator of this ...-Dr. Cory Berkland. Additional Information-Madison & Lila Self Graduate Fellow. Show More about Biography. 1132 Learned Hall 1530 W 15th St. Lawrence, KS 66045 Bus Route: 29 [email protected] 785-864-5258. facebook instagram twitter youtube linkedin. Admissions; Research Labs; People; Forms; Colloquium; School of Engineering; myKU; Visit KU; Apply ...Introduction. With approximately 174,000 cases per year, luminal breast cancers are the most common forms of breast cancer diagnosed in the US and Canada [1, 2].In contrast to Her2-overexpressing breast cancers, or triple negative breast cancers, which lack expression of estrogen receptor (ER), Progesterone receptor, and Her2, luminal breast cancers frequently express hormone and Her2 ...Sep 1, 2022 · Abstract: Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles. Type: Grant. Filed: August 16, 2019. Date of Patent: February 14, 2023. Assignee: ADARE PHARMACEUTICALS USA, INC. Inventors: Cory Berkland, Milind Singh. AU - Berkland, Cory. AU - Kim, Kyekyoon. AU - Pack, Daniel W. N1 - Funding Information: This work was partly supported by NIH grant EB002878. We would like to thank Larry Markoski and Prof. Jeff Moore for helping us with their time and equipment to make SEC measurements. The piroxicam gift from Dongwha Pharmaceuticals is also gratefully ...Cory Berkland holds the Solon E. Summerfield Distinguished Professorship in the Department of Pharmaceutical Chemistry and in the Department of Chemical Engineering at The University of Kansas. He received MS and PhD degrees from the Department of Chemical and Biomolecular Engineering at the University of Illinois in …Cory Berkland, CEO [email protected]. Release Summary. Phase Ia/b will assess the safety of BBI-001 and test the ability of BBI-001 to prevent iron uptake from food. Contacts.Cory Berkland. The Berkland Lab investigates pharmaceuticals and biomaterials. They aim to understand the transport of pharmaceuticals as a function of physical and chemical properties. Biomaterials are also investigated for applications in regenerative medicine. Faculty Profile. Berkland Research Lab.We welcome panelists: Cory Berkland, PhD. Cory Berkland, PhD: Cory Berkland holds the Solon E. Summerfield Distinguished Professorship in the Department of Pharmaceutical Chemistry and in the Department of Chemical Engineering at The University of Kansas.He will be starting as a Professor in the Biomedical Engineering Department and the …Berkland C, Kim K, Pack DW. PLG microsphere size controls drug release rate through several competing factors . Pharmaceutical Research . 2003 Jul 1;20(7):1055-1062. doi: 10.1023/A:1024466407849Zahra Mohammadi, Amanda Cole and Cory J. Berkland . In Situ Synthesis of Iron Oxide within Polyvinylamine Nanoparticle Reactors. The Journal of Physical Chemistry C 2009, 113 (18) , 7652-7658. DOI: 10.1021/jp901036b. Zahra Mohammadi, Amanda Cole and Cory J. Berkland . In Situ Synthesis of Iron Oxide within Polyvinylamine Nanoparticle Reactors. ...LAWRENCE — Cory Berkland might not be the first person you’d guess would help to create what has become a multimillion-dollar company. The distinguished professor, appointed in the departments of Pharmaceutical Chemistry and Chemical & Petroleum Engineering at the University of Kansas, grew up on a pig farm in Iowa, …AU - Berkland, Cory J. N1 - Funding Information: The authors are thankful to the University of Kansas, KS, USA, Washington University, St. Louis, MO, USA, the Deanship of Scientific Research (DSR) at King Abdulaziz University, and the Mohamed Saeed Tamer Chair for Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia for ... Abdulgader A. Baoum1 and Cory J. Berkland1,2,* 1Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS ... Baoum and Berkland Page 3 J Pharm Sci. Author manuscript; available in PMC 2014 October 23. NIH-PA Author Manuscript. gene delivery in vivo28,39-41. One approach for overcoming this limitation was to link theBrittany L Hartwell 1 , Chad J Pickens 2 , Martin Leon 3 , Cory Berkland 1 2 4 Affiliations 1 Bioengineering Graduate Program, University of Kansas 1520 West 15th Street, Lawrence, Kansas 66045, United States.Dr. Brian T. Andrews is a Plastic Surgeon in Iowa City, IA. Find Dr. Andrews's phone number, address, insurance information, hospital affiliations and more.19‏/08‏/2012 ... Cory Berkland is in the business of making drugs work, and he's just one in a long line of Kansas University researchers who have ...Cory Berkland spun Austin, Texas-based Savara Inc. out of his University of Kansas lab in 2007 to develop aerosolized drug therapies. It's the first company wPRECLINICAL STUDY The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells Wei Bin Fang • Min Yao • Iman Jokar • Nabil Alhakamy • Cory Berkland • Jin Chen • Dana Brantley-Sieders • Nikki Cheng Received: 4 December 2014/Accepted: 24 February 2015/Published online: 6 March 2015Cory Berkland. The University of Kansas. Verified email at ku.edu. Drug Delivery Formulation Controlled Release. Articles Cited by Public access Co ... YY Lin, M Laird Forrest, CJ Berkland. Expert opinion on drug delivery 6 (11), 1175-1194, 2009. 461: 2009: Fabrication of PLG microspheres with precisely controlled and monodisperse size ...Qingting Hu, 1 Megan Myers, 1 Wei Fang, 1 Min Yao, 1 Gage Brummer, 1 Justin Hawj, 1 Curtis Smart, 1 Cory Berkland, 2 and Nikki Cheng 1, 3, * Qingting Hu 1 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USANumber of Employee Profiles 2. Bond Biosciences has 2 current employee profiles, including Co-founder and Chief Scientific Officer Cory Berkland. Cory Berkland Co-founder and Chief Scientific Officer.Cory Berkland. Bioengineering Graduate Program, University of Kansas, Lawrence, Kansas. Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas. Departemant of Chemical and Petroleum Engineering, University of Kansas, Lawrence, Kansas. Correspondence to: C. Berkland (e-mail: [email protected])Search for more papers by ...Dr. Hartwell obtained her Ph.D. in biomolecular engineering with Cory Berkland at the University of Kansas as a Madison and Lila Self Graduate Fellow. Her doctoral research focused on developing an antigen-specific immunotherapy to treat multiple sclerosis while determining cellular and molecular mechanisms of tolerance.. Nathan H. Dormer, Jennifer Nelson-Brantley, Hinrich Staeckeliquid droplets (Berkland et al. 2001). Cory Berkland has 3 current jobs including Co-founder and Chief Executive Officer at Bond Biosciences, Co-founder and Chief Scientific Officer at Bond Biosciences, and Solon E. Summerfield Distinguished Professor at University of Kansas. Additionally, Cory Berkland has had 1 past job as the Chief Science/Scientist at Orbis Biosciences. Cory Berkland joins the faculty Nov. 1 f Cory BERKLAND | Cited by 10,026 | of University of Kansas, Kansas (KU) | Read 243 publications | Contact Cory BERKLANDMay 5, 2008 · The most common forms of proteosomes used for vaccine applications are nanoparticles composed of the outer membrane proteins (OMPs) of Neisseria meningitidis. OMPs have been used successfully in a marketed meningococcal vaccine since 1981 and are considered non-toxic and well-tolerated [160], [161]. The company's lead candidate, BBI-001, is an ...

Continue Reading